Delcath Systems, Inc. (NASDAQ:DCTH) Short Interest Up 8.0% in March

Delcath Systems, Inc. (NASDAQ:DCTHGet Free Report) saw a significant increase in short interest in March. As of March 15th, there was short interest totalling 898,900 shares, an increase of 8.0% from the February 29th total of 832,700 shares. Based on an average trading volume of 235,400 shares, the short-interest ratio is currently 3.8 days.

Insider Transactions at Delcath Systems

In other news, Director Gil Aharon bought 26,882 shares of Delcath Systems stock in a transaction dated Tuesday, March 19th. The stock was purchased at an average price of $3.72 per share, for a total transaction of $100,001.04. Following the purchase, the director now directly owns 1,069,710 shares in the company, valued at approximately $3,979,321.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 21.10% of the stock is currently owned by insiders.

Institutional Trading of Delcath Systems

Several institutional investors have recently bought and sold shares of the company. AIGH Capital Management LLC purchased a new stake in shares of Delcath Systems during the 4th quarter valued at about $4,918,000. BVF Inc. IL purchased a new position in shares of Delcath Systems in the second quarter valued at about $6,872,000. Vivo Capital LLC boosted its stake in Delcath Systems by 57.4% in the 3rd quarter. Vivo Capital LLC now owns 1,855,191 shares of the company’s stock worth $7,514,000 after purchasing an additional 676,404 shares during the period. Stonepine Capital Management LLC purchased a new position in Delcath Systems during the second quarter valued at $2,098,000. Finally, Worth Venture Partners LLC bought a new stake in shares of Delcath Systems in the fourth quarter worth about $1,224,000. 61.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on DCTH shares. HC Wainwright raised their target price on Delcath Systems from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, March 27th. upgraded shares of Delcath Systems to a “sell” rating in a research report on Wednesday, March 27th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $18.50.

Check Out Our Latest Research Report on DCTH

Delcath Systems Price Performance

Shares of Delcath Systems stock traded up $0.10 during midday trading on Wednesday, reaching $4.80. 14,118 shares of the company’s stock traded hands, compared to its average volume of 219,001. Delcath Systems has a 12 month low of $2.25 and a 12 month high of $7.99. The stock has a 50 day moving average of $4.39 and a 200-day moving average of $3.84.

Delcath Systems (NASDAQ:DCTHGet Free Report) last issued its quarterly earnings results on Tuesday, March 26th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.19. The company had revenue of $0.54 million during the quarter, compared to analysts’ expectations of $0.48 million. Delcath Systems had a negative net margin of 2,308.86% and a negative return on equity of 563.60%. During the same period last year, the company posted ($0.86) EPS. As a group, equities research analysts forecast that Delcath Systems will post -1.45 earnings per share for the current year.

About Delcath Systems

(Get Free Report)

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

See Also

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with's FREE daily email newsletter.